Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Gilead's GS-5829 flops in mCRPC

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Gilead's GS-5829 flops in mCRPC

BearDownAZ

Jul 13, 2022 11:03AM

Re: Gilead's GS-5829 flops in mCRPC

Nextblockbuster

Jul 13, 2022 12:40PM

Re: Gilead's GS-5829 flops in mCRPC

tada

Jul 19, 2022 04:42PM

Re: Gilead's GS-5829 flops in mCRPC

fouremm

Jul 19, 2022 11:47PM

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Gilead's GS-5829 flops in mCRPC

in response to

Re: Gilead's GS-5829 flops in mCRPC

fouremm

posted on Jul 20, 2022 09:26AM

fouremm - Thank you that is exactly what I was thinking about.

That points out the risk in biotech even better. Gilead, a pretty large biotech/pharma just failed on a second drug candidate. We sure have our challenges but the science continues to shine through.